Latest News Archive

Please select Category, Year, and then Month to display items

International Award for UFS Department of Nuclear Medicine

07 July 2023 | Story André Damons | Photo Supplied

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

Plant-strengthening agent a result of joint effort between UFS and German company

2015-07-27

Research over the past few years has showed that the agent applied mostly as a foliar spray subsequently leads to better seedlings as well as growth and yield enhancement of various crops.

The application of a plant-strengthening agent in the agricultural industry has, until recently, been largely ignored, says Dr Elmarie van der Watt of the Department of Soil, Crop, and Climate Sciences at the University of the Free State (UFS). The agent was co-developed by researchers at the UFS and a German company.

The product is moving into new markets, such as China, Vietnam, the USA, and Australia.

ComCat® was the result of extensive research by the German company Agraforum AG. Commercialisation was limited initially to Europe, while research was expanded to other parts of the world, with the University of the Free State as the main research centre. ComCat® is a unique, non-toxic plant strengthening agent derived from wild plants. It enhances plant growth and yield, as well as resistance against abiotic and biotic stress factors.

Dr Van der Watt says that, in nature, plants communicate and interact by means of allelochemicals (the inherent silent tool of self-protection among plants) and other phytochemicals (chemical compounds that occur naturally in plants), as part of their resistance mechanisms towards biotic and abiotic stress conditions.

Most wild-plant varieties are usually well-adapted to resist these stress factors. However, monoculture crops have lost this ability to a large extent. “Active compounds contained in extracts from wild plants applied to monoculture crops can potentially supply the signal for the latter to activate their dormant resistance mechanisms.”

Research over the past few years has showed that the agent applied mostly as a foliar spray subsequently leads to better seedlings as well as growth and yield enhancement of various crops. A major advantage is that, despite its enhancing effects on root development and yield, it does not induce unwanted early vegetative growth that could jeopardise the final yield, as happened in the past for nitrogen application at an early growth stage.

Dr Van der Watt says, “Physiological data on the effect of the natural bio-stimulant product on photosynthesis, respiration, and resistance towards biotic stress conditions indicate that it can be regarded as a useful tool to manipulate agricultural crops. Research also showed that the field of application for this natural product is never-ending, and new applications are being investigated every day.”

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept